UCL Cancer Institute, University College London, London, United Kingdom.
UCL Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom.
Clin Cancer Res. 2019 Dec 15;25(24):7436-7447. doi: 10.1158/1078-0432.CCR-19-0360. Epub 2019 Sep 24.
Photoacoustic imaging (PAI) is a novel noninvasive and nonionizing imaging technique that allows longitudinal imaging of tumor vasculature and monitoring of response to therapy, especially for vascular targeted chemotherapy agents. In this study, we used a novel high-resolution all-optical PAI scanner to observe the pharmacodynamic response to the vascular-disrupting agent OXi4503.
Two models of colorectal carcinoma (SW1222 and LS174T) that possess differing pathophysiologic vascularization were established as subcutaneous tumors in mice. Monitoring of response was performed over a 16-day "regrowth" period following treatment at 40 mg/kg, and at day 2 for a "dose response" study at 40 mg/kg, 10 mg/kg, 1 mg/kg, and sham dose.
Qualitative and quantitative changes in PA signal are observed, with an initial decrease followed by a plateau and subsequent return of signal indicating regrowth. Both tumor types exhibited a decrease in signal; however, the more vascularized SW1222 tumors show greater response to treatment. Decreasing the dose of OXi4503 led to a decrease in PA signal intensity of 60%, 52%, and 20% in SW1222 tumors and 30%, 26%, and 4% for LS174T tumors.
We have shown for the first time that PAI can observe the pharmacodynamic response of tumor vasculature to drug treatment both longitudinally and at different dose levels. Assessment of differing response to treatment based on vascular pathophysiologic differences among patients has the potential to provide personalized drug therapy; we have demonstrated that PAI, which is clinically translatable, could be a powerful tool for this purpose.
光声成像是一种新颖的无创、非电离成像技术,可实现肿瘤血管的纵向成像和对治疗反应的监测,尤其适用于血管靶向化疗药物。在本研究中,我们使用新型高分辨率全光学光声成像扫描仪观察了对血管破坏剂 Ox i4503 的药效反应。
建立了两种具有不同病理血管化的结直肠癌(SW1222 和 LS174T)模型,作为皮下肿瘤植入小鼠体内。在以 40mg/kg 进行治疗后的 16 天“再生长”期间,以及在以 40mg/kg、10mg/kg、1mg/kg 和假剂量进行“剂量反应”研究的第 2 天,进行了反应监测。
观察到 PA 信号的定性和定量变化,初始信号下降,随后出现平台,随后信号恢复表明再生长。两种肿瘤类型均表现出信号下降;然而,血管化程度更高的 SW1222 肿瘤对治疗的反应更大。降低 Ox i4503 的剂量导致 SW1222 肿瘤的 PA 信号强度降低 60%、52%和 20%,LS174T 肿瘤降低 30%、26%和 4%。
我们首次表明,光声成像可以纵向和不同剂量水平观察肿瘤血管对药物治疗的药效反应。根据患者血管病理生理差异评估不同的治疗反应有可能提供个性化药物治疗;我们已经证明,具有临床转化潜力的光声成像可以成为实现这一目标的有力工具。